Design Therapeutics Future Growth
Future criteria checks 0/6
Design Therapeutics's earnings are forecast to decline at 17.7% per annum while its annual revenue is expected to grow at 91.5% per year. EPS is expected to decline by 15% per annum.
Key information
-17.7%
Earnings growth rate
-15.0%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 91.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Oct 04
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Jun 19Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Mar 15Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Nov 16Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Jun 06Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Feb 09Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Oct 25Design Therapeutics GAAP EPS of -$0.27 misses by $0.02
Aug 08We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Jul 02Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Mar 18Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Dec 03Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Aug 18Design Therapeutics expands board of directors
Jun 07Design Therapeutics EPS misses by $0.24
May 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -79 | N/A | N/A | 3 |
| 12/31/2025 | N/A | -67 | N/A | N/A | 3 |
| 12/31/2024 | N/A | -52 | N/A | N/A | 3 |
| 9/30/2024 | N/A | -48 | -46 | -46 | N/A |
| 6/30/2024 | N/A | -51 | -51 | -51 | N/A |
| 3/31/2024 | N/A | -59 | -54 | -54 | N/A |
| 12/31/2023 | N/A | -67 | -59 | -59 | N/A |
| 9/30/2023 | N/A | -72 | -61 | -61 | N/A |
| 6/30/2023 | N/A | -74 | -61 | -60 | N/A |
| 3/31/2023 | N/A | -69 | -58 | -57 | N/A |
| 12/31/2022 | N/A | -63 | -52 | -51 | N/A |
| 9/30/2022 | N/A | -57 | -46 | -45 | N/A |
| 6/30/2022 | N/A | -51 | -41 | -40 | N/A |
| 3/31/2022 | N/A | -43 | -39 | -38 | N/A |
| 12/31/2021 | N/A | -36 | -31 | -29 | N/A |
| 9/30/2021 | 0 | -28 | -24 | -23 | N/A |
| 6/30/2021 | 0 | -19 | -17 | -17 | N/A |
| 3/31/2021 | 0 | -13 | -10 | -10 | N/A |
| 12/31/2020 | 0 | -8 | -9 | -9 | N/A |
| 12/31/2019 | 1 | -2 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DSGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DSGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DSGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DSGN is forecast to have no revenue next year.
High Growth Revenue: DSGN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DSGN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 12:11 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Design Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Goldman Sachs |
| Joseph Schwartz | Leerink Partners LLC |
| Yasmeen Rahimi | Piper Sandler Companies |